May 15th 2024 12:00 PM Eastern Daylight Time
Cell Response: launches proprietary synthetic-lethality screening platform, Resistome™, to combat cancer drug resistance.
LONDON--Cell Response Ltd announced today the launch of its flagship synthetic lethality platform, Resistome™, to transform the way cancer drug resistance is overcome.
Cell Response’s proprietary synthetic-lethality screening platform, Resistome™, rapidly identifies drug-specific resistance mechanisms and evaluates first-in-class drugs and combinations which can overcome drug-specific resistance to extend life for patients, as well as identifying refined biomarker strategies to improve the stratification of patients for treatment.
Cell Response’s Resistome platform provides Pharmaceutical and Biotech companies with a unique opportunity to capture a growing market for novel first-in-class drugs and combinations which overcome resistance to existing first-in-class drugs.
Yoram Altschuler, Founder and CEO said “Over 90% of cancer patient mortality is due to drug resistance. Resistome is a truly ground-breaking approach to rapidly discovering novel solutions to cancer drug resistance. Our synthetic-lethality platform uses to power of a miniaturized screen of 1000s of gene constructs in parallel on a single Resistome ‘chip’ to rapidly and cost-effectively identify the genes and pathways responsible for drug-specific resistance. What would take years and 10s of millions of dollars with conventional technology we can complete in weeks to months at a fraction of the cost, and with far greater precision.”
About Cell Response
Cell Response is a global leader in the field of cancer drug resistance. Resistome™ represents a paradigm shift for drug discovery and development to identify drug-specific resistance mechanisms, develop and test first-in-class drugs and combinations to combat resistance, stratify patients using refined biomarker strategies, rank cancer subtypes and patient groups for label expansion, as well as develop a deep understanding of a drug’s specific mechanism of action and off-target activity to optimize a drug’s therapeutic window.
Contact
Media enquiries
Jon Waterman-Smith